Analyst Francois Brisebois of LifeSci Capital maintained a Buy rating on Dyne Therapeutics, boosting the price target to $40.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Francois Brisebois has given his Buy rating due to a combination of factors that highlight the potential of Dyne Therapeutics in the RNA therapeutics landscape. The recent acquisition of Avidity Biosciences by Novartis for $12 billion is seen as a positive signal for Dyne, as it underscores the growing interest of big pharmaceutical companies in RNA-based therapies. This acquisition not only validates the market potential of RNA therapeutics but also positions Dyne favorably due to its competing programs, particularly in the treatment of DM1.
Brisebois emphasizes that Dyne’s derisked registration data for DM1, expected in mid-2026, supports the company’s accelerated approval pathway in the U.S., potentially allowing Dyne to be first-to-market. The company’s strategic increase in patient enrollment aims to enhance the statistical significance of its clinical outcomes, which is crucial for achieving accelerated approval. Furthermore, the acquisition by Novartis is anticipated to boost sales growth, further validating the commercial potential of RNA therapies, and indirectly benefiting Dyne’s valuation. These factors collectively contribute to the Buy rating, reflecting confidence in Dyne’s future prospects.
Brisebois covers the Healthcare sector, focusing on stocks such as Kala Pharmaceuticals, Avadel Pharmaceuticals, and Praxis Precision Medicines. According to TipRanks, Brisebois has an average return of -2.9% and a 37.30% success rate on recommended stocks.
In another report released today, Piper Sandler also reiterated a Buy rating on the stock with a $48.00 price target.